Latest mitral valve disease Stories
--Researchers Presented Positive Preclinical Data That Set the Stage for Longer-Term Tiara Studies Now Underway and Human Trials Planned for 2013-- --Researchers Also Presented Preliminary Registry Study Results Showing Improved Clinical Status in Refractory Angina Patients Implanted with Neovasc Reducer(TM)-- TSX Venture Exchange: NVC VANCOUVER, Oct. 23, 2012 /PRNewswire/ - Neovasc Inc. (TSXV: NVC) today announced that its Tiara(TM) transcatheter mitral valve in...
--Neovasc's Tiara(TM) Transcatheter Mitral Valve Selected for Inclusion in "Best" New Device Concepts for 2012 Session-- --Other Presentations Include Tiara Project Update and Neovasc Reducer(TM) Preliminary Registry Results-- TSX Venture Exchange: NVC VANCOUVER, Oct. 18, 2012 /PRNewswire/ - Neovasc Inc. (TSXV: NVC) today announced that researchers will present data on the company's two major development products at the upcoming 24(th) Annual Transcatheter Cardiovascular...
--Presentations will Highlight Promising Results from Animal Studies-- TSX Venture Exchange: NVC VANCOUVER, May 14, 2012 /PRNewswire/ - Neovasc Inc. (TSXV: NVC), a developer of novel technologies to treat vascular disease, today announced that its Tiara(TM) technology under development for the transcatheter treatment of mitral valve disease will be featured in three scientific sessions at EuroPCR 2012, the annual meeting of the European Association for Percutaneous...
--Grew Annual Revenues 21% Year-Over-Year to $5.3 Million-- --Received CE Mark for Neovasc Reducer(TM) in Europe and Advanced Tiara(TM) Transcatheter Mitral Valve Program-- TSX Venture Exchange: NVC VANCOUVER, April 25, 2012 /PRNewswire/ - Neovasc Inc. (TSXV: NVC), today announced financial results for the year ended December 31, 2011. "2011 was an eventful year for Neovasc," said Alexei Marko, CEO of Neovasc. "We received CE mark designation for the Neovasc Reducer(TM)(...
TSX Venture Exchange: NVC -- Robust Rise in Contract Manufacturing Helps Fuel 41% Year-Over-Year Revenue Increase -- -- Successful Financing Generated Cash to Fund Key Milestones for High Potential Reducer(TM) and Tiara(TM) New Product Programs -- VANCOUVER, Nov. 2, 2011 /PRNewswire/ - Neovasc Inc. (TSXV: NVC), today announced financial results for the three and nine months ended September 30, 2011. "This has been a good quarter for Neovasc, with strong revenue growth...
The Cleveland Clinic and Intuitive Surgical, Inc. will present a live webcast on OR-Live.com featuring a roundtable discussion on the treatment of asymptomatic mitral valve disease. Moderator Julie Huang, M.D., staff cardiologist in the Section of Clinical Cardiology, Department of Cardiovascular Medicine; Brian P. Griffin, MD, FACC, staff cardiologist in the Section of Cardiovascular Imaging, Department of Cardiovascular Medicine; A. Marc Gillinov, MD, staff cardiac surgeon; and Tomislav...
